DEX-implant (46 eyes) | Bevacizumab (42 eyes) | P value | |
Mean follow-up, days (CI) | 1366 (1215 to 1516) | 1488 (1364 to 1611) | 0.2 |
Baseline BCVA, letters (SD) | 55.5 (12.5) | 56.3 (11.9) | 0.75 |
Baseline CMT, µm (SD) | 474.3 (95.9) | 503 (140.9) | 0.38 |
Number of eyes that had 5-year follow-up | 26 | 26 | 0.61 |
Baseline phakic eyes | 30 | 32 | 0.81 |
Baseline NPDR | 31 | 32 | 0.58 |
BCVA, best corrected visual acuity; CMT, central macular thickness; DEX, dexamethasone; NPDR, non-proliferative diabetic retinopathy.